TAIHO PHARMACEUTICAL CO., LTD.のNews Releases

Taiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris Biotech

about 2 months ago

Solar Power Generation Facility Launched at Taiho Pharmaceutical's Kitajima Plant to Accelerate Carbon Neutrality Initiatives

3 months ago

Otsuka Group Selected for CDP Climate Change A List for a Third Consecutive Year

3 months ago

Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy

4 months ago

Taiho Innovations, LLC. Selected as a Registered Venture Capital in AMED's Strengthening Program for Pharmaceutical Startup Ecosystem

6 months ago

Taiho Pharmaceutical and Haihe Biopharma Announce the Launch of MET Inhibitor HAIYITAN ® Tablets 50mg in Japan

8 months ago

Taiho Pharmaceutical Exercises Option for an Exclusive License to Quemliclustat in Japan and Certain Territories in Asia

10 months ago

Taiho Pharmaceutical Establishes New Company, Arirge Co., Ltd., to Address Social Issues Related to Cancer

11 months ago

Taiho Pharmaceutical Co., Ltd. announced today that it has established a new...

Otsuka Pharmaceutical and Taiho Pharmaceutical Commence Material Recycling of Waste PTP Used in Pharmaceutical Packaging

12 months ago

Corporate Venture Capital Firm Taiho Ventures Selected for AMED's Strengthening Program for Pharmaceutical Startup Ecosystem

about 1 year ago

Taiho Pharmaceutical Launches Solmack® Q-Arl D, Chewable Tablets for Diarrhea Caused by Overeating and Overdrinking that Can Be Taken Anywhere Without Water - A New Addition to the Solmack Product Line

about 1 year ago

Taiho Pharmaceutical Co., Ltd. announced that it launched Solmack® Q-Arl D, a...

Taiho Pharma Enters Exclusive License Agreement with Haihe Biopharma for Gumarontinib (SCC244), an Agent for Non-Small Cell Lung Cancer

about 1 year ago